We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.75 | 17.50 | 18.00 | 17.75 | 17.75 | 17.75 | 58,159 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.25 | 16.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/12/2016 10:33 | 20K buy just through on isdx. What an amazing buying opportunity. Excellent scientific and commercial progress made during 2016, and I'm sure many here would agree 2017 will be the year of the real action. The company believes developments on the scientific front "have the potential to rapidly accelerate the Company's growth." And here we're sat pretty much at the year low. Unbelievable. Not long to wait now until the trend reverses IMO, which of course could happen in a flash at any time. | parob | |
07/12/2016 15:12 | colinzeal, i should think he has not got any firm news for that post. But sure to anything we are due some exciting news soon and the sooner it comes the better to stop this downtrend. As we all know a certain Tom w has been shouting from the rooftop for ages "news before Christmas", which has thus far been proved to be just idle words. His outfit may well still have a large holding after he top sliced a few at 100 so whether to believe him is another matter. But just who can you believe these days. Certainly no one on a BB is to be trusted. | neftanikoff | |
07/12/2016 14:04 | Me too, buying HCM - 3 new global blockbuster cancer drugs to be launched in 2017 which will be material in terms of the Company valuation | nerdofsteel | |
07/12/2016 13:35 | Couldn't help what , JJ ? Buying more shares here or downvoting Mazz because you have a crush on him?! | dogwalker | |
07/12/2016 09:53 | They normally drop one in the morning one mid day and one towards close. | john henry | |
07/12/2016 09:51 | Daily 10k sells as as regular as clockwork. | john henry | |
07/12/2016 09:25 | Do not worry boys,girls, at least two new deals will be done soon. | diamond fibre | |
07/12/2016 08:18 | Couldn't help it | judijudi | |
06/12/2016 20:23 | F3rdinand, . . . . and then there's 6. Skinbiotix (which you sort of alluded to) and 7. a treatment for Parkinson's disease. SOH won't be too disappointed if all chickens don't come home to roost - but I will be; call it greed? 7 out of 7 and nothing less. So let's call a spade a spade - it's a 7-bagger, minimum. And 2017 is about right. I'm logging this for a repeat and "told you so" post sometime next year. | owenmo | |
06/12/2016 20:12 | Indeed, Neft - TW have mentioned P&G at least twice over several months. I still believe they are involved. I would go as far as say I expect them to be the MN launching our first cardiovasculare product in spring 2017. | elrico | |
06/12/2016 20:12 | To the person who downvoted every one of my comments today: do you have a crush on me or something? | mazzstar | |
06/12/2016 19:38 | parob, DSM yes, but you know very well P & G has been cited for a very long time, am i right ? | neftanikoff | |
06/12/2016 18:50 | One of the biggest opportunities is the ability to enhance the growth rate of specific microbes. The success of which has been shown recently. It swings open the door for deals right across the space From probiotic manufacturers to the animal feed markets. The dsm deal being a multi billion £ ingredient supplier gave opti early industry financial backing and its confidence. This targeted approach to improve the growth rate which can increase efficacy of a product is revolutionary. It gives the opportunity to not only use this tech to optimise Optis lpldl strain (which has already been shown) but many already on the market - starting with DSM. You can be pretty certain multiple deals with global players will materialise to optimise their products. Especially as the science is becoming clearer, giving more reasons for suppliers to use this tech to stay ahead of the curve. It Is jam tomorrow as this is still revolutionary science, the fact a deal such as this struck so early shows huge confidence in Optis tech. | riskybusiness1 | |
06/12/2016 17:39 | Basically what we're saying here is that OPTI will pretty much have a slice of every pie in the next few years... 1. Food will contain OPTI's calorie free sugars. 2. The nation will be losing weight through OPTI's slimbiome 'revolution'. 3. Cardiovascular disease will be slashed with our supplements and most probably pharma products prescribed by the NHS in years to come. 4. Beauty products will be adapted to bring health benefits/ work better. 5. Wounds and infections will be diminished through our technology. All massive markets...as others have rightly mentioned- all we need here is one MN deal and then the belief in the microbiome and thus in OPTI will increase tenfold. That's why i'm adding more while the wider market ignores our progress. | f3rdinand | |
06/12/2016 17:29 | Thank you someuwin ;) This could be exciting! | mazzstar | |
06/12/2016 17:25 | Good research mazz! | someuwin | |
06/12/2016 17:25 | parob nitpick my words why don't you. You should know what I mean by support and confidence behind the product and to spell it out for you since it's not clear enough I meant A CONFIRMED DEAL! | mazzstar | |
06/12/2016 17:23 | I'm thinking shampoo I'm thinking Johnson & Johnson. | mazzstar | |
06/12/2016 17:14 | I googled Cath O'Neill and came across a job that was posted 2 weeks ago. Interesting that it mentions the scalp, I wonder what Opti are up to...? 'Research Technician in Musculoskeletal and Dermatological Sciences. You will be engaged full time in research to investigate the microbiota of the scalp in healthy individuals and those with dandruff. This work will involve studying barrier markers in ex vivo skin innoculated with scalp microbiota, as a model system. You will be part of a team which investigates skin barrier function in health and disease and how the microbiota interact with the epidermal barrier. You must have at least a B.Sc in a biological science, or equivalent experience. Previous experience in the fields of skin biology or microbiology will be an advantage...Enquirie hxxps://www.totaljob | mazzstar | |
06/12/2016 17:08 | Mazz, you've just said:"It's not even revenues we should be concerned about, it is industry confidence and support behind these products.""OptiBioti | parob | |
06/12/2016 17:05 | true parob but support with £££ | mazzstar |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions